Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept.

@article{Ramien2011SevereRE,
  title={Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept.},
  author={Michele L Ramien and Alexander U. J. Wong and Jay S. Keystone},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2011},
  volume={52 5},
  pages={e133-5}
}
Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Azathioprine as a Steroid Sparing Agent in Recalcitrant Type 2 Reaction

Dr. Raju Chaudhary, Dr. Khushbu Modi
2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Treatment of recurrent erythema nodosum leprosum with infliximab.

The New England journal of medicine • 2006
View 3 Excerpts
Highly Influenced

Towards understanding the pathology of erythema nodosum leprosum.

Transactions of the Royal Society of Tropical Medicine and Hygiene • 2008
View 1 Excerpt

A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum

LG Villahermosa, TT Jr.Fajardo, RM Abalos
Am J Trop Med Hyg • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…